Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.

Citation: Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J.: Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem, Volume 55 (20), 2012
Authors: Atrash B, Avery S, Bavetsias V, Bayliss R, Blagg J., Box G, Brown N, Bush K, Crumpler S, de Haven Brandon A, Eccles SA, Faisal A, Henley A, Kosmopoulou M, Linardopoulos S, Moore AS, Raynaud FI, Sheldrake PW, Sun C, Valenti M, Workman P
Journal: J Med Chem
Year: 2012
DOI: 10.1021/jm300952s
PubMed: 23043539
Machine-readable: REST API RDF

Publication